8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 19, 2026·SEC
Zynex, Inc.(ZYXI)Earnings, Financials & Key Ratios
ZYXI•NASDAQ
$0.06
0.6× P/E·Price updated Jun 20, 2026
AboutZynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Show more
- Revenue$192M+4.4%
- EBITDA$11M-28.2%
- Net Income$3M-69.2%
- EPS (Diluted)0.09-66.7%
- Gross Margin79.5%+0.4%
- EBITDA Margin5.6%-31.2%
- Operating Margin3.11%-46.8%
- Net Margin1.56%-70.5%
- ROE7.32%-57.7%
ZYXI Price & Volume
Zynex, Inc. (ZYXI) stock price & volume — 10-year historical chart
Loading chart...
Severe Revenue Contraction Triggers Deep Equity Erosion
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital structure insolvency risk
Key Thesis Takeaways
- Zynex faces a critical inflection point as its core electrotherapy business experiences a 73.3% year-over-year revenue collapse, leading to a $42.9 million net loss in 2025Q3.
- The company's financial stability is increasingly compromised by a negative equity position of $41.4 million and a current ratio that has plummeted to 0.47.
- Investors should exercise extreme caution as the firm struggles to reconcile high fixed operating costs with a rapidly deteriorating top-line, raising significant concerns regarding long-term business viability.
Verdict Logic
the company's current ratio of 0.47 and the shift to a $41.4 million equity deficit indicate severe solvency risks that outweigh any potential valuation appeal.
ZYXI Growth Metrics
Zynex, Inc. (ZYXI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years32.99%
5 Years33.44%
3 Years13.86%
TTM-44.13%
Profit CAGR
10 Years-
5 Years-20.61%
3 Years-44.06%
TTM-1633.13%
EPS CAGR
10 Years-
5 Years-18.48%
3 Years-39.18%
TTM-1741.28%
Return on Capital
10 Years179.4%
5 Years17.26%
3 Years12.38%
Last Year5.36%
Peers Comparison
Key metrics vs top competitors for Zynex, Inc. (ZYXI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.06 | $1.67M | 0.61 | 4.36% | 1.56% | 7.32% | 0.51% | |
| $1.35 | $93.94M | -2.29 | 99.17% | -24.48% | -139.83% | — | |
| $237.00 | $5.91B | 20.47 | 18.58% | 9.95% | 24.88% | — | |
| $78.83 | $10.63B | 20.11 | 16.65% | 18.92% | 13.04% | — | |
| $95.84 | $166.94B | 25.76 | 5.67% | 13.91% | 12.09% | — | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — |
Compare ZYXI vs Peers
Zynex, Inc. (ZYXI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZYXI SEC Filings & Documents
Zynex, Inc. (ZYXI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ZYXI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZYXI Frequently Asked Questions
Zynex, Inc. (ZYXI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Zynex, Inc.'s revenue?
Zynex, Inc. (ZYXI) reported $108.2M in revenue for fiscal year 2024. This represents a 871513% increase from $0.0M in 1998.
How fast is Zynex, Inc. growing?
Zynex, Inc. (ZYXI) grew revenue by 4.4% over the past year. Growth has been modest.
Is ZYXI profitable?
Zynex, Inc. (ZYXI) reported a net loss of $74.0M for fiscal year 2024.
Dividend & Returns
Does ZYXI pay dividends?
Yes, Zynex, Inc. (ZYXI) pays a dividend with a yield of 0.51%. This makes it attractive for income-focused investors.
What is ZYXI's return on equity?
Zynex, Inc. (ZYXI) has a return on equity (ROE) of 7.3%. This is below average, suggesting room for improvement.
What is Zynex, Inc.'s free cash flow?
Zynex, Inc. (ZYXI) had negative free cash flow of $21.0M in fiscal year 2024, likely due to heavy capital investments.